When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...
Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and ...
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...
Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...
Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...
Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 ...
The study of VK2735 among obese adults found those taking the highest dosage of 100 milligrams had an average weight loss of 8.2% from baseline over a four-week period. The 100 mg dose also ...
你是否在减肥药物的选择上感到困惑？在肥胖症日益成为全球性健康挑战的当下，治疗肥胖的药物市场呈现出前所未有的活力与竞争。在这波健康浪潮中，Viking Therapeutics公司推出的VK2735减肥药吸引了广泛的关注，专家预测这款药物有潜力挑战目前市场上的领航者——诺和诺德的Wegovy和礼来的Zepbound。 肥胖的危害不言而喻，它不仅影响外貌，更与糖尿病、心脏病等多种慢性疾病密切相关。尽管 ...
Data reported earlier Monday from Viking Therapeutics (NASDAQ:VKTX) on its weight loss medicine VK2735 indicates that Novo ...
Despite reduction in VK2735 exposure, significant reductions in body weight were observed, with subjects reporting mean body weight change of -4.0% from baseline at Day 28 (p<0.0001).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback